The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
Each program will rely on partnerships between Novartis teams and local networks—including health authorities, community organizations and private sector groups
The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” strengthens Alpha Cognition’s existing portfolio supporting both ALPHA-1062 and ZUNVEYL
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
